However, statistically significant data emerged regarding IL-13 levels in relation to the treatment of the EoE group with proton pump inhibitors (PPIs): after 8 weeks of treatment, a significant increase in IL-13 was recorded (p = 0.03), and regarding endoscopic advancement assessed by EREFS, a strong and statistically significant negative correlation was found with fibrostenotic EREFS after treatment, and a moderate negative correlation with total EREFS after treatment. This evidence concerns the gene IL13 and eosinophilic esophagitis.